Daré Bioscience, in collaboration with Strategic Science & Technologies, has announced positive topline data from a Phase 2b study evaluating Sildenafil Cream as a treatment for female sexual arousal disorder (FSAD). The study showed meaningful improvement in the Arousal-Sensation Domain of the Sexual Function Questionnaire for patients treated with Sildenafil Cream. Additionally, improvements were observed in secondary and exploratory endpoints related to…
